FindTrial
Sign In

Clinicopathological study of women with endometrial hyperplasia.

clinicopathological study of women with endometrial hyperplasia - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/11/077211
Enrollment
50
Registered
2024-11-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N925- Other specified irregular menstruation

Interventions

Intervention1: medroxyprogesterone: oral medroxyprogesterone is a pre approved drug for treatment of endometrial hyperplasia Intervention2: mirena: mirena is intra uterine device used for treatment of

Sponsors

maulana azad medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: all patients visiting the OPD between 35-65 years

Exclusion criteria

Exclusion criteria: women below 35 years and above 65 years no males

Design outcomes

Primary

MeasureTime frame
treatment outcome of women with endometrial hyperplasia after 6 monthsTimepoint: at 6 weeks and 6 months—

Secondary

MeasureTime frame
association of risk factors to endometrial hyperplasia typeTimepoint: percentage wise type of disease associated with known risk factors—

Countries

India

Contacts

Public Contactdr latika sahu

maulana azad medical college

latikasahu@gmail.com9654962666

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026